New insights into pancreatic cancer-induced paraneoplastic diabetes

Raghuwansh P. Sah, Sajan Jiv Singh Nagpal, Debabrata Mukhopadhyay, Suresh T Chari

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Up to 85% of patients with pancreatic cancer have diabetes or hyperglycaemia, which frequently manifests as early as 2-3 years before a diagnosis of pancreatic cancer. Conversely, patients with new-onset diabetes have a 5-8-fold increased risk of being diagnosed with pancreatic cancer within 1-3 years of developing diabetes. Emerging evidence now indicates that pancreatic cancer causes diabetes. As in type 2 diabetes, β-cell dysfunction and peripheral insulin resistance are seen in pancreatic cancer-induced diabetes. However, unlike in patients with type 2 diabetes, glucose control worsens in patients with pancreatic cancer in the face of ongoing, often profound, weight loss. Diabetes and weight loss, which precede cachexia onset by several months, are paraneoplastic phenomena induced by pancreatic cancer. Although the pathogenesis of these pancreatic cancer-induced metabolic alterations is only beginning to be understood, these are likely mechanisms to promote the survival and growth of pancreatic cancer in a hostile and highly desmoplastic microenvironment. Interestingly, these metabolic changes could enable early diagnosis of pancreatic cancer, if they can be distinguished from the ones that occur in patients with type 2 diabetes. One such possible biomarker is adrenomedullin, which is a potential mediator of β-cell dysfunction in pancreatic cancer-induced diabetes.

Original languageEnglish (US)
Pages (from-to)423-433
Number of pages11
JournalNature Reviews Gastroenterology and Hepatology
Volume10
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Pancreatic Neoplasms
Type 2 Diabetes Mellitus
Weight Loss
Adrenomedullin
Cachexia
Early Detection of Cancer
Hyperglycemia
Vascular Resistance
Insulin Resistance
Biomarkers
Glucose
Survival

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

New insights into pancreatic cancer-induced paraneoplastic diabetes. / Sah, Raghuwansh P.; Nagpal, Sajan Jiv Singh; Mukhopadhyay, Debabrata; Chari, Suresh T.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 10, No. 7, 07.2013, p. 423-433.

Research output: Contribution to journalArticle

@article{68e2067fbb2e4c3fb88ccf8aafa68aef,
title = "New insights into pancreatic cancer-induced paraneoplastic diabetes",
abstract = "Up to 85{\%} of patients with pancreatic cancer have diabetes or hyperglycaemia, which frequently manifests as early as 2-3 years before a diagnosis of pancreatic cancer. Conversely, patients with new-onset diabetes have a 5-8-fold increased risk of being diagnosed with pancreatic cancer within 1-3 years of developing diabetes. Emerging evidence now indicates that pancreatic cancer causes diabetes. As in type 2 diabetes, β-cell dysfunction and peripheral insulin resistance are seen in pancreatic cancer-induced diabetes. However, unlike in patients with type 2 diabetes, glucose control worsens in patients with pancreatic cancer in the face of ongoing, often profound, weight loss. Diabetes and weight loss, which precede cachexia onset by several months, are paraneoplastic phenomena induced by pancreatic cancer. Although the pathogenesis of these pancreatic cancer-induced metabolic alterations is only beginning to be understood, these are likely mechanisms to promote the survival and growth of pancreatic cancer in a hostile and highly desmoplastic microenvironment. Interestingly, these metabolic changes could enable early diagnosis of pancreatic cancer, if they can be distinguished from the ones that occur in patients with type 2 diabetes. One such possible biomarker is adrenomedullin, which is a potential mediator of β-cell dysfunction in pancreatic cancer-induced diabetes.",
author = "Sah, {Raghuwansh P.} and Nagpal, {Sajan Jiv Singh} and Debabrata Mukhopadhyay and Chari, {Suresh T}",
year = "2013",
month = "7",
doi = "10.1038/nrgastro.2013.49",
language = "English (US)",
volume = "10",
pages = "423--433",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - New insights into pancreatic cancer-induced paraneoplastic diabetes

AU - Sah, Raghuwansh P.

AU - Nagpal, Sajan Jiv Singh

AU - Mukhopadhyay, Debabrata

AU - Chari, Suresh T

PY - 2013/7

Y1 - 2013/7

N2 - Up to 85% of patients with pancreatic cancer have diabetes or hyperglycaemia, which frequently manifests as early as 2-3 years before a diagnosis of pancreatic cancer. Conversely, patients with new-onset diabetes have a 5-8-fold increased risk of being diagnosed with pancreatic cancer within 1-3 years of developing diabetes. Emerging evidence now indicates that pancreatic cancer causes diabetes. As in type 2 diabetes, β-cell dysfunction and peripheral insulin resistance are seen in pancreatic cancer-induced diabetes. However, unlike in patients with type 2 diabetes, glucose control worsens in patients with pancreatic cancer in the face of ongoing, often profound, weight loss. Diabetes and weight loss, which precede cachexia onset by several months, are paraneoplastic phenomena induced by pancreatic cancer. Although the pathogenesis of these pancreatic cancer-induced metabolic alterations is only beginning to be understood, these are likely mechanisms to promote the survival and growth of pancreatic cancer in a hostile and highly desmoplastic microenvironment. Interestingly, these metabolic changes could enable early diagnosis of pancreatic cancer, if they can be distinguished from the ones that occur in patients with type 2 diabetes. One such possible biomarker is adrenomedullin, which is a potential mediator of β-cell dysfunction in pancreatic cancer-induced diabetes.

AB - Up to 85% of patients with pancreatic cancer have diabetes or hyperglycaemia, which frequently manifests as early as 2-3 years before a diagnosis of pancreatic cancer. Conversely, patients with new-onset diabetes have a 5-8-fold increased risk of being diagnosed with pancreatic cancer within 1-3 years of developing diabetes. Emerging evidence now indicates that pancreatic cancer causes diabetes. As in type 2 diabetes, β-cell dysfunction and peripheral insulin resistance are seen in pancreatic cancer-induced diabetes. However, unlike in patients with type 2 diabetes, glucose control worsens in patients with pancreatic cancer in the face of ongoing, often profound, weight loss. Diabetes and weight loss, which precede cachexia onset by several months, are paraneoplastic phenomena induced by pancreatic cancer. Although the pathogenesis of these pancreatic cancer-induced metabolic alterations is only beginning to be understood, these are likely mechanisms to promote the survival and growth of pancreatic cancer in a hostile and highly desmoplastic microenvironment. Interestingly, these metabolic changes could enable early diagnosis of pancreatic cancer, if they can be distinguished from the ones that occur in patients with type 2 diabetes. One such possible biomarker is adrenomedullin, which is a potential mediator of β-cell dysfunction in pancreatic cancer-induced diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84879974685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879974685&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2013.49

DO - 10.1038/nrgastro.2013.49

M3 - Article

VL - 10

SP - 423

EP - 433

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 7

ER -